2. Signaling Pathways
  3. Neuronal Signaling
  4. Amino Acid Decarboxylase
  5. Amino Acid Decarboxylase Inhibitor

Amino Acid Decarboxylase Inhibitor

Amino Acid Decarboxylase Inhibitors (9):

Cat. No. Product Name Effect Purity
  • HY-W016814
    (Z)-Aconitic acid
    		Inhibitor 99.28%
    (Z)-Aconitic acid is an orally active glutamate decarboxylase inhibitor. (Z)-Aconitic acid reduces IκB-α phosphorylation. (Z)-Aconitic acid inhibits Antigen-induced arthritis and Monosodium urate (HY-B2130A)-induced gout.
  • HY-W012906
    L-Allylglycine
    		Inhibitor 98.0%
    L-Allylglycine (L-2-Allylglycine) is an amino acid derivative. L-Allylglycine is an inhibitor for glutamate decarboxylase (GAD) that reduces the GABA biosynthesis in the brain. L-Allylglycine exhibits convulsant activity.
  • HY-W016349
    Chelidamic acid
    		Inhibitor 99.93%
    Chelidamic acid is a heterocyclic organic acid with a pyran skeleton. Chelidamic acid has good coordination ability with noble metal ions. Chelidamic acid is also one of the most potent inhibitors of glutamate decarboxylase, with a Ki of 33 μM.
  • HY-W015595
    L-Allylglycine hydrochloride
    		Inhibitor 98.0%
    L-Allylglycine (L-2-Allylglycine) hydrochloride is an amino acid derivative. L-Allylglycine hydrochloride is an inhibitor for glutamate decarboxylase (GAD) that reduces the GABA biosynthesis in the brain. L-Allylglycine hydrochloride exhibits convulsant activity.
  • HY-115822
    α-Fluoromethylhistidine dihydrochloride
    		Inhibitor 99.1%
    α-Fluoromethylhistidine dihydrochloride is an orally active histidine decarboxylase inhibitor. α-Fluoromethylhistidine dihydrochloride depletes histamine in enterochromaffin-like (ECL) cells, reduces the number and volume density of secretory vesicles in ECL cells, and does not affect histamine storage in mast cells. α-Fluoromethylhistidine dihydrochloride abolishes Omeprazole (HY-B0113)-induced vacuolization of ECL cells and decreases gastrin-induced histamine efflux from ECL cells. α-Fluoromethylhistidine dihydrochloride does not alter the granular characteristics of ECL cells, omeprazole-induced hypertrophy of ECL cells, gastrin-induced pancreastatin-like immunoreactivity efflux, nor does it affect gastric acid secretion induced by histamine or vagal stimulation. α-Fluoromethylhistidine dihydrochloride inhibits basal and gastrin-stimulated gastric acid secretion, reduces acid output induced by gastrin+IBMX (HY-12318), but does not directly affect acid generation in isolated parietal cells.
  • HY-103391
    Qc1
    		Inhibitor 98.20%
    Qc1 is a reversible and noncompetitive threonine dehydrogenase (TDH) inhibitor. Qc1 can be used for the research of Metabolic disease.
  • HY-W1015419
    α-FMH
    		Inhibitor
    α-FMH (α-Fluoromethylhistidine) is an orally active histidine decarboxylase inhibitor. α-FMH depletes histamine in enterochromaffin-like (ECL) cells, reduces the number and volume density of secretory vesicles in ECL cells, and does not affect histamine storage in mast cells. α-FMH abolishes Omeprazole (HY-B0113)-induced vacuolization of ECL cells and decreases gastrin-induced histamine efflux from ECL cells. α-FMH does not alter the granular characteristics of ECL cells, omeprazole-induced hypertrophy of ECL cells, gastrin-induced pancreastatin-like immunoreactivity efflux, nor does it affect gastric acid secretion induced by histamine or vagal stimulation. α-FMH inhibits basal and gastrin-stimulated gastric acid secretion, reduces acid output induced by gastrin+IBMX (HY-12318), but does not directly affect acid generation in isolated parietal cells.
  • HY-U00065
    Tritoqualine
    		Inhibitor
    Tritoqualine is a histidine decarboxylase inhibitor, that inhibits the release of histidine.
  • HY-103391R
    Qc1 (Standard)
    		Inhibitor
    Qc1 (Standard) is the analytical standard of Qc1 (HY-103391). This product is intended for research and analytical applications. Qc1 is a reversible and noncompetitive threonine dehydrogenase (TDH) inhibitor. Qc1 can be used for the research of Metabolic disease.